HKSE:01763 (China)
Â
Ordinary Shares - Class H
HK$
10.82
(+5.25%)
Apr 26
Business Description
China Isotope & Radiation Corp
ISIN : CNE1000031F4
Share Class Description:
HKSE:01763: Ordinary Shares - Class HCompare
Compare
Traded in other countries / regions
01763.Hong Kong IPO Date
2018-07-06Description
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.71 | |||||
| Equity-to-Asset | 0.36 | |||||
| Debt-to-Equity | 0.36 | |||||
| Debt-to-EBITDA | 1.77 | |||||
| Interest Coverage | 22.26 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.47 | |||||
| Beneish M-Score | -2.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.6 | |||||
| 3-Year EBITDA Growth Rate | 10.1 | |||||
| 3-Year EPS without NRI Growth Rate | 10 | |||||
| 3-Year FCF Growth Rate | 12.9 | |||||
| 3-Year Book Growth Rate | 6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.33 | |||||
| 9-Day RSI | 64.66 | |||||
| 14-Day RSI | 56.12 | |||||
| 6-1 Month Momentum % | -4.67 | |||||
| 12-1 Month Momentum % | -32.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.93 | |||||
| Quick Ratio | 1.73 | |||||
| Cash Ratio | 0.68 | |||||
| Days Inventory | 90.37 | |||||
| Days Sales Outstanding | 207.87 | |||||
| Days Payable | 64.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.42 | |||||
| Dividend Payout Ratio | 0.48 | |||||
| 3-Year Dividend Growth Rate | 44.9 | |||||
| Forward Dividend Yield % | 3.14 | |||||
| 5-Year Yield-on-Cost % | 4.65 | |||||
| Shareholder Yield % | 3.89 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 52.48 | |||||
| Operating Margin % | 12.13 | |||||
| Net Margin % | 5.59 | |||||
| FCF Margin % | 10.22 | |||||
| ROE % | 8.12 | |||||
| ROA % | 3.01 | |||||
| ROIC % | 7.52 | |||||
| ROC (Joel Greenblatt) % | 23.31 | |||||
| ROCE % | 11.72 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.53 | |||||
| PE Ratio without NRI | 10.72 | |||||
| PEG Ratio | 1.82 | |||||
| PS Ratio | 0.47 | |||||
| PB Ratio | 0.67 | |||||
| Price-to-Tangible-Book | 0.72 | |||||
| Price-to-Free-Cash-Flow | 4.66 | |||||
| Price-to-Operating-Cash-Flow | 4.66 | |||||
| EV-to-EBIT | 1.9 | |||||
| EV-to-EBITDA | 1.9 | |||||
| EV-to-Revenue | 0.27 | |||||
| EV-to-FCF | 2.25 | |||||
| Price-to-Projected-FCF | 0.25 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.25 | |||||
| Price-to-Graham-Number | 0.59 | |||||
| Earnings Yield (Greenblatt) % | 52.63 | |||||
| FCF Yield % | 21.42 | |||||
| Forward Rate of Return (Yacktman) % | 30.61 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers